Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

CombiGene: Strategic consequences after CG01 - VH Corp

Lärkberget

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
* Implementing cost savings and new priorities
* New propositions from the main shareholder
* Our revised fair value estimate is SEK 8.27 (12.19) per share

In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again after reaching a return agreement with Spark Therapeutics. The company was also focused on developing the COZY programme for chronic pain. After evaluating the status of CG01, CombiGene decided to end the project and prioritise the COZY programme, with emphasis on the gene therapy COZY02. The company will also implement cost savings to prolong its financial runway. In Västra Hamnen’s webcast, CEO Peter Ekolind explained the reasons behind these decisions. Shortly after the webcast, the company’s largest shareholder proposed strategic changes, which shareholders will vote on in December. After a review, our estimated value is 8.27 SEK per share.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team